Last update 21 Nov 2024

Zinostatin Stimalamer

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SMANX, Zinostatin, Zinostatin stimalamer (JAN/INN)

+ [4]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Liver Cancer

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 4739280

Source: *****

100 Clinical Results associated with Zinostatin Stimalamer

100 Translational Medicine associated with Zinostatin Stimalamer

100 Patents (Medical) associated with Zinostatin Stimalamer

137

Literatures (Medical) associated with Zinostatin Stimalamer

03 Oct 2015·Expert Review of Anticancer TherapyQ3 · MEDICINE

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Q3 · MEDICINE

Review

Author: Lefèvre, Raphael ; Grand-Dewyse, Pierre ; Mandawala, Chalani ; Durand-Dubief, Mickael ; Alphandéry, Edouard

Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS), Pegasys and PegIntron, BIND-014, CRLX-101, Oncaspar, Neulasta, Aurimmune, Auroshell, AuNPs, Nanotherm, NanoXray, Magnetosome chains, Kadcyla (T-DM1), Ontak (DAB/IL2), Gendicine and Curcumin. We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.

01 Apr 2014·Current Drug TargetsQ4 · MEDICINE

Recent Advances in Active Hepatic Targeting Drug Delivery System

Q4 · MEDICINE

Review

Author: Zhai, Guangxi ; Du, Hongliang ; Wang, Yang

Hepatic diseases are turning into one of the few diseases that cannot be effectively cured due to some reasons although various receptors existed in the liver. Currently, several passive targeting delivery systems have been used in the drug/gene delivery for the treatment of hepatic diseases. For example, Zinostatin stimalamer (trade name of Smancs(®)), a drug-polymer conjugate, was launched in Japan in 1994, which treats hepatocellular carcinoma. More improtantly, different measures would be taken in accord to the specified cell that was lesioned or dysfunctioned via interaction between homing ligands and target receptors so as to improve accumulation of drugs in the target cell and to reduce nonspecific toxicity towards other cells or organs. Therefore, it is urgent to design novel delivery systems that physically or chemically grafted homing devices in order to improve the targeting properties of drugs in specific cell sites. From that perspective, the present article highlights recent development of active hepatic targeting drug/gene delivery systems for the treatment of hepatic diseases that were mediated by some kinds of receptors including asialoglycoprotein receptors (ASGP-R), glycyrrhetinic acid receptor (GA-R), glycyrrhizin receptor (GL-R), hyaluronan receptor (HA-R) and so on.

01 Dec 2012·Journal of Controlled ReleaseQ1 · MEDICINE

Macromolecular therapeutics in cancer treatment: The EPR effect and beyond

Q1 · MEDICINE

Review

Author: Maeda, Hiroshi

In this review, I have discussed various issues of the cancer drug targeting primarily related to the EPR (enhanced permeability and retention) effect, which utilized nanomedicine or macromolecular drugs. The content goes back to the development of the first polymer-protein conjugate anticancer agent SMANCS and development of the arterial infusion in Lipiodol formulation into the tumor feeding artery (hepatic artery for hepatoma). The brief account on the EPR effect and its definition, factors involved, heterogeneity, and various methods of augmentation of the EPR effect, which showed remarkably improved clinical outcomes are also discussed. Various obstacles involved in drug developments and commercialization are also discussed through my personal experience and recollections.

100 Deals associated with Zinostatin Stimalamer

External Link

KEGG	Wiki	ATC	Drug Bank
D03240	Zinostatin Stimalamer	A05BA	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Liver Cancer	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2009	Phase 2	Hepatocellular Carcinoma	126	SM-11355	ncommovnae(ijdwkjaahn) = whdzjyfwdj wqsdrazhwx (arkucfmqcr ) View more	-	20 May 2009
				Zinostatin stimalamer	ncommovnae(ijdwkjaahn) = duwalwjxwx wqsdrazhwx (arkucfmqcr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Zinostatin Stimalamer

Overview

Basic Info

Gene Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation